Drug intelligence / Profile preview

AAV-TERT-03

Development stage: Preclinical
Lead developer: Telomere Therapeutics
Modality: Gene Therapies
Administration: Intravenous

Overview

AAV-TERT-03 is an adeno-associated virus (AAV) gene therapy candidate under development by Telomere Therapeutics. It is designed to deliver a functional copy of the telomerase reverse transcriptase (TERT) gene to adult tissues. The therapeutic objective is to restore or maintain telomerase activity, thereby counteracting telomere shortening, a process linked to cellular senescence and various degenerative diseases. While the company's lead program, AAV-TERT-01, is focused on Idiopathic Pulmonary Fibrosis (IPF), the specific target indication for AAV-TERT-03 has not yet been disclosed. The program is currently in the preclinical proof-of-concept stage of development.

Targets

TERT (Telomerase)

Beyond the preview

Go deeper on AAV-TERT-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV-TERT-03.

Explore the full profile